The trkC locus encodes catalytic and noncatalytic receptors, generated by alternative splicing. These primary high-affinity neurotrophin-3 (NT-3) receptors may act in concert to modulate responsiveness to NT-3. Signal modulation can also be achieved by receptors that are post-translationally processed. We report that the noncatalytic TrkC receptor, TrkCNC2, is cleaved at the membrane-proximal region of its extracellular domain. This generates a soluble ectodomain (gp90
Neurotrophins are major regulators of neural system development. This growth factor family comprises nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), -4/5, -6 and -7 (Go¨tz et al., 1994; Barbacid, 1995; Nilsson et al., 1998) . Neurotrophins bind to two classes of receptors: the p75 NTR receptor and the members of the Trk receptor tyrosine kinase family (Barbacid, 1995) .
Complexity of Trk family members (TrkA, TrkB and TrkC) increases as new receptor forms are identified.
They are generated by alternative splicing that takes place in the extracellular region, thus conferring different ligand-binding specificities (Clary and Reichardt, 1994; Strohmaier et al., 1996; Ninkina et al., 1997) . Splicing also occurs in the intracellular domain, as described for TrkB and TrkC. Thus, we can distinguish catalytic isoforms that exhibit tyrosine kinase (TK) activity from noncatalytic forms in which the TK domain was substituted by specific cytoplasmic sequences (Klein et al., 1990; Middlemas et al., 1991; Lamballe et al., 1993; Tsoulfas et al., 1993; Valenzuela et al., 1993; Garner and Large, 1994; Shelton et al., 1995; Menn et al., 1998) .
All these variants act in concert to modulate responsiveness to neurotrophins. The various catalytic TrkC receptor isoforms (TrkC K), differing by the presence or absence of inserts in the TK domain, display distinct biological responses upon NT-3 stimulation, resulting from different signaling capabilities (Lamballe et al., 1993; Tsoulfas et al., 1993; Valenzuela et al., 1993) . As for the noncatalytic receptors, two TrkB (Klein et al., 1990; Middlemas et al., 1991) and five TrkC noncatalytic isoforms have been identified so far (Lamballe et al., 1993; Tsoulfas et al., 1993; Valenzuela et al., 1993; Garner and Large, 1994; Shelton et al., 1995) . Although their biological function remains elusive, it has been postulated that truncated TrkB receptors control diffusion and internalization of their cognate ligand (Biffo et al., 1995) , and act as dominant negatives on their catalytic counterpart (Eide et al., 1996) .
We previously reported that the noncatalytic TrkCNC2 receptor is highly expressed either alone or with its catalytic counterpart, in the central and peripheral nervous system (Menn et al., 1998) . In vivo studies showed that trkC NC2 transcripts were abundant in regions of neuronal maturation. In addition, TrkC NC2 expression in neural stem cells coincided with the exit of neural progenitors from the cell cycle, suggesting its involvement in neuronal and glial cell differentiation (Menn et al., 2000) . Interestingly, these data are in agreement with a study reporting that TrkCNC2 was capable of inducing neuronal differentiation of avian neural crest cells in collaboration with p75 NTR (Hapner et al., 1998) . Moreover, in mature neurons, TrkCNC2 distribution was specifically restricted to distinct areas of extending neurites, suggesting its involvement in synaptic plasticity and neuronal survival (Menn et al., 2000) .
Interestingly, NT-3 as well as TrkC null mutant mice suffer from cardiac malformation (Donovan et al., 1996; Tessarollo et al., 1997) . Since these deficiencies are not observed in TrkC catalytic receptor mutants, it suggests that NT-3 effects are mainly mediated during heart development by noncatalytic TrkC receptors that are highly expressed in the cardiovascular system (Menn et al., 1998) . Taken together, these data suggest that the TrkCNC2 receptor acts either alone or in association with its catalytic counterpart. It could, therefore, account for specific local effects of NT-3 or modulate TrkC catalytic-mediated response to NT-3.
Response to neurotrophins can also be modulated by the existence of truncated receptor isoforms generated by cleavage of the native protein. As previously described for the p75 NTR and TrkA receptors, this post-translational proteolysis generates a soluble and a membrane-bound fragment (DiStephano and Johnson, 1988; Zupan et al., 1989; Cabrera et al., 1996) . The latter is capable of signaling, as described for TrkA (DiazRodriguez et al., 1999) , whereas the released ectodomain can function as an antagonist or a ligand carrier molecule.
To test if TrkC proteins were also subjected to such post-translational modifications, we investigated the presence of shorter forms in NIH3T3 cells overexpressing the TrkC catalytic and noncatalytic receptors. These cells proved useful in defining interactions of the various neurotrophins with their specific receptors (Klein et al., 1991a, b; Lamballe et al., 1991) and delineating the biological properties of the different TrkC catalytic isoforms (Lamballe et al., 1993) .
To undertake this study, we subcloned full-length trkC NC2 and trkC K cDNAs into the mammalian expression vector pMEXneo (Martin-Zanca et al., 1989) and transfected these plasmids into NIH3T3 cells. Immunoprecipitation and Western blot analyses were then performed on lysates of G418-resistant colonies as indicated in Figure 1 . Antibodies used were directed against either the specific NC2 cytoplasmic domain (anti-NC2), the catalytic TK domain (anti-K) or the extracellular domain of the TrkC receptor (anti-Ext). Specificity of these immune sera was assessed in previous studies (Menn et al., 1998 (Menn et al., , 2000 . Both NC2 and Ext antisera identified two major protein species with apparent molecular masses of 110 and l00 kDa, likely to represent the mature form and the partially glycosylated precursor, respectively ( Figure 1a) . In addition to . Cells were routinely grown in DMEM supplemented with 10% newborn calf serum (NCS) and 400 mg/ml G418 (Gibco-BRL). (a) Proteins were extracted into ice-cold RIPAE buffer (1 Â PBS; 1% Triton X-100; 1% SDS; 5 mm EDTA; 1% aprotinin; 10 mg/ml sodium desoxycholate). Cellular proteins (250 mg) were incubated at 41C with either anti-NC2 (in the presence (+) or absence (À) of the competing immunizing antigen) or anti-K sera and protein A Sepharose (Sigma). Immune complexes were then resolved by 12% SDS-PAGE. After transfer onto Immobilon-P membranes (Millipore), Western blot analysis was performed with the primary antibody (anti-NC2, and anti-Ext at 1 : 2000; anti-HA at 1 : 5000, anti-K at 1 : 1000). Membranes were then incubated for 1 h with horseradish peroxidase-conjugated secondary antibody (donkey anti-rabbit (Amersham): 1 : 20 000 for anti-NC2, anti-Ext and anti-K, sheep anti-rat (Roche): 1 : 10 000 for anti-HA). Finally, proteins were visualized by chemiluminescence (ECL west dura, Pierce). (b) Culture media from cell monolayers were collected and concentrated on Centricon 30 (Amicon). A total of 250 mg of protein was resolved by 8% SDS-PAGE, and analysed by Western blot using anti-Ext antibodies. Anti-NC2 and anti-EXT antibodies were previously described (Menn et al., 2000) . Anti-K serum (Calbiochem) recognizes specifically the TrkC catalytic receptor. Monoclonal antibody to the HA epitope (derived from the influenza haemagglutinin protein) was purchased from Roche. That p20 TrkCNC2 was recognized by the anti-NC2 but not the anti-Ext serum, indicated that this polypeptide corresponded to a TrkCNC2 protein fragment containing, at least, the NC2-specific sequence, likely to derive from cleavage of the native protein. In this case, we would expect to detect in the culture medium a polypeptide corresponding to at least part of the receptor extracellular domain. Therefore, we searched for the presence of this polypeptide in NIH NC2 culture medium by direct Western blot analysis with anti-Ext serum, after concentration on centricon-30 membranes. We detected a band of about 90 kDa (gp90 TrkCNC2 ), presumably containing extracellular sequences of the TrkC protein (Figure 1b) .
The presence of a cleaved receptor protein was detected in several TrkCNC2-overexpressing NIH3T3 clones, by using different NC2-specific antibodies (data not shown). Interestingly, there was a direct correlation between the detectable amount of full-length receptor protein ( gp110 TrkCNC2 ) and that of p20
TrkCNC2 in the multiple clones analysed, suggesting that the presence of p20
TrkCNC2 was linked to synthesis of the TrkCNC2 receptor.
To confirm this possibility, we also transfected NIH3T3 cells with a trkCNC2 cDNA containing an HA epitope fused to its carboxy-terminal part. Lysates of NC2-HA stably expressing NIH3T3 cells (NIH NC2-HA ), immunoprecipitated with anti-NC2 antibodies, and analysed by Western blotting with an anti-HA serum, revealed the same pattern as described above (Figure 1a ). This indicated that the 20 kDa polypeptide was derived from the TrkCNC2 receptor and corresponded to its carboxy-terminal region. Taken together, these results showed that p20
TrkCNC2 is a novel TrkCNC2 form that corresponds to the carboxy-terminal part of the protein and is presumably generated by cleavage of the fulllength protein. A similar experiment was performed on TrkCK-expressing NIH3T3 cells (NIH K ) with anti-K antibodies. Besides the two bands corresponding to the partially and fully glycosylated receptor (gp120 TrkCK and gp145 TrkCK ), respectively, we did not detect a band(s) that could account for a shorter form of the catalytic receptor (Figure 1a) .
Since the relative molecular mass of p20
TrkCNC2
suggested that the cleavage took place close to the transmembrane region, we analysed the distribution of this protein in subcellular fractions of NIH NC2 cells, stimulated with NT-3 (see below), by Western blotting with NC2-specific antiserum. As expected, full-length gp100
TrkCNC2 and gp110 TrkCNC2 proteins were essentially detected in the plasma membrane fraction. However, a very small amount of these proteins was also found in the microsomes, possibly as a consequence of receptor internalization required for its recycling and transport of newly synthesized proteins to the plasma membrane. p20
TrkCNC2 was detected in the microsomal and plasma membrane fractions but not in the nuclear and cytosolic fractions (Figure 2a) . While full-length and truncated forms of the TrkCNC2 receptor were localized in the same cellular compartments, their relative ratios differed depending on the fractions. Thus, the gp110 TrkCNC2 / p20
TrkCNC2 ratio was much lower in the microsomal fraction, where p20
TrkCNC2 was highly expressed. This result rules out a possible contamination of the microsomal fraction by that of other cell compartments. TrkCNC2 is a membrane-bound protein. NIH NC2 cells were starved for 48 h, then stimulated with NT-3 (50 ng/ml, Promega) for 15 min. They were then lysed in hypotonic buffer (20 mm HEPES; 1 mm MgCl 2 ; 1mm KC1; 2 mm AEBSF; 1 mm EDTA; 20 mm leupeptin; 22.5 mg/ml aprotinin) containing 0.5% Triton X-100. They were then subjected to a low-speed centrifugation (90 g, 10 min). The nuclear pellet was resuspended in hypotonic buffer containing 0.1% Triton X-100, loaded on sucrose cushions (2.2 and 1.6 m) and submitted to a 45 min centrifugation at 80 000 g. The recovered pellet contained nuclei. Supernatant of the lowspeed centrifugation was centrifuged at 12 000 g for 30 min. The pellet contained the plasma membranes. The supernatant was then ultracentrifuged at 100 000 g for 1 h. The pellet contained the microsomal fraction and the supernatant contained the cytosol. All fractions were submitted to immunoprecipitation and Western blot as described above, with anti-NC2 (a) or anti-PCNA (1 : 1000, Roche), anti-FnR (fibronectin receptor/integrin a5, 1 : 1000, Calbiochem), anti-Mek (1 : 2000, provided by Dr Pouyssegur), as indicated (b). Total cell lysate (T), nuclear (N), microsomal (m), cytosolic (C) and membrane (Mb) fractions. Positions of molecular weight markers are shown (a). Size of the bands revealed by the various antibodies is indicated (b)
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Efficient separation of cell fractions was assessed by the presence of specific markers, that is, the nuclear PCNA protein, the cytosolic Mek protein and the fibronectin receptor as a marker of membranes (Figure 2b ). This showed that p20 TrkCNC2 is a membrane-associated protein. Together with the recovery of a 90 kDa polypeptide in the culture medium, these results indicated that cleavage occurred within the extracellular juxtamembrane region.
We next investigated whether receptor stimulation by NT-3, the only known ligand for TrkC (Lamballe et al., 1991) , could modulate p20
TrkCNC2 expression. Following addition of a saturating concentration of NT-3 to NIH NC2 cells, we found that the level of p20
TrkCNC2 increased within 15 min and remained stable during 45 min (Figure 3a) . Interestingly, we observed an increase in the amount of gp90 TrkCNC2 released in the culture media, concomitant with the accumulation of the p20
TrkCNC2 protein in the cell (Figure 3a ). This upregulation of TrkCNC2 cleavage upon NT-3 stimulation is in agreement with previous reports describing ligand-induced cleavage of different classes of receptors, including tyrosine kinase receptors such as TrkA (Cabrera et al., 1996) and c-Kit (Yee et al., 1993) , as well as that of other receptor types such as Notch (Schroeter et al., 1998) . Moreover, untreated NIH NC2 cells, maintained in the presence of 10% serum, also expressed the p20
TrkCNC2 protein, although to a lesser extent (Figure 3b ), indicating the existence of a basal cleavage of the TrkCNC2 receptor in absence of NT-3 stimulation.
Mechanisms responsible for receptor cleavage, upon neurotrophin stimulation, have not been elucidated yet. It is possible that this effect could be mediated by NT-3 activation of second messengers such as PKC, as described for NGF (Pandiella et al., 1986) . Treatment of NIH NC2 cells with 12-O-tetradecanoylphorbol-13-acetate (TPA) resulted in the accumulation of p20 TrkCNC2 in the cells, although to a lesser extent, as compared to NT-3 stimulation (Figure 3c ). Since cleavage of several receptor tyrosine kinases have been described (Zupan et al., 1989; Cabrera et al., 1996; Vecchi et al., 1998) , we performed parallel experiments on cells expressing the TrkC catalytic isoform. Untreated NIH K cells, maintained in 10% serum, do not express a truncated version of the catalytic receptor (Figure 1a) . Interestingly, treatment of NIH K cells with either NT-3 or TPA did not induce processing of the catalytic receptor (data not shown). This could be explained by structural differences between the two classes of receptors. Thus, folding of the TrkC catalytic receptor would render it unaccessible to the protease(s) that cleaves TrkCNC2.
The results described above indicated that TrkCNC2 cleavage occurred near the juxtamembrane region. To characterize the protease(s) possibly responsible for p20
TrkCNC2 generation, we tested the effects of different protease inhibitors on TrkCNC2 cleavage after NT-3 stimulation (Figure 4, table) . We found that only ethylenediaminetetraacetic acid (EDTA) and 1.10 phenanthroline could impair TrkCNC2 cleavage in a concentration-dependent manner, within the micromolar range (Figure 4b, table) . None of the other inhibitors, listed in the table, had an effect on TrkCNC2 cleavage. This strongly suggested that cleavage of TrkCNC2 is mediated by a metalloprotease(s), which is in agreement with previous reports that cleavage of other neurotrophin receptors, such as TrkA and p75 NTR also involved metalloproteases (DiStephano et al., 1993; Diaz-Rodriguez et al., 1999) .
Finally, to rule out the possibility that generation of p20
TrkCNC2 was merely a consequence of ectopic receptor expression in fibroblasts, we investigated its presence in lysates of cortical neurons cultured in NT-3-and serumdeprived medium, and of adult mouse brain, previously shown to express endogenous TrkCNC2 protein (Menn et al., 1998 (Menn et al., , 2000 . Interestingly, we detected the presence of p20
TrkCNC2
, in addition to that of the mature full-length TrkCNC2 receptor (gp105 TrkCNC2 ), by immunoprecipitation followed by Western blot analysis with anti-NC2 serum ( Figure 5 ). Variability in molecular weight of the TrkCNC2 full-length receptor between NIH NC2 cells ( Figure 1a ) and cortical neurons ( Figure 5 ) probably reflects differences in receptor glycosylation. The relative intensity of the 20 kDa band to that of the 105 kDa band, in cortical neurons, was significantly higher (Figure 5) , as compared to that observed in NIH NC2 cell lysates (Figure 1a ). Since cortical neurons were found to synthesize NT-3 (data not shown), this could be because of an increased accumulation of the truncated protein following autocrine NT-3 stimulation. We also analysed the existence of truncated form of the TrkC catalytic receptor in cortical neurons, in the cleavage is stimulated by NT-3, TPA and serum. Quiescent NIH NC2 cells were stimulated with NT-3 (50 ng/ ml) for the indicated periods of time (a). Culture media were collected, concentrated on centricon-30. Total proteins (250 mg) were separated on 8% SDS-PAGE. Western blot analysis was then performed with the anti-EXT serum (a, upper panel) . Cell lysates were immunoprecipitated with anti-NC2, and resolved by 12% SDS-PAGE. Western blot analysis was then performed with anti-NC2 antibodies (a, lower panel). Quiescent NIH NC2 cells (0.5%) were stimulated with 10% serum or NT-3 (50 ng/ml) (b) or TPA (160 mm) (c) for 15 min. As described in panel a, proteins of cell lysates were immunoprecipitated with anti-NC2, resolved by 12% SDS-PAGE, and submitted to Western blot analysis with anti-NC2 antibodies (b, c) presence or absence of NT-3 stimulation. Since the antibody used recognized both the TrkB and TrkC catalytic receptors, we found that none of these two catalytic isoforms was processed. Thus, preferential cleavage of TrkCNC2, over that of the catalytic isoform, was not only observed in NIH3T3 cells but also appears to take place in vivo.
In summary, we report processing of the noncatalytic TrkCNC2 receptor upon NT-3 stimulation in fibroblasts and cortical neurons. Despite the fact that the exact site of receptor cleavage is not known, several hypotheses can be raised regarding its physiological relevance.
Cleavage of TrkCNC2, which does not occur in the TrkC catalytic isoform, could represent part of an autocrine regulatory loop modulating NT-3 activity in cortical neurons. Result of the subcellular fractionation suggests that cleavage occurs either when the TrkCNC2 receptor is localized at the cell membrane or following its internalization in microsomes. In the first case, generation of the ectodomain may control NT-3 availability by titrating the ligand or by facilitating its release outside of the cell. However, the fact that the highest level of p20 protein expression is detected in the microsome fraction suggests that cleavage mainly occurs within the cell, and consequently, that NT-3 becomes internalized with TrkCNC2. Cleavage would then occur as the receptor is localized in the microsomes. As a result, NT-3 would be released inside the cell, and therefore represents an intracellular neurotrophin pool capable of binding to the catalytic TrkC or the p75 NTR receptors for anterograde transport, for example, as it has been described in RGCs cells (Butowt and Von Bartheld, 2001) .
Another possibility would be that proteolytic cleavage may trigger downmodulation of TrkCNC2 by accelerating its rate of recycling. Such a mechanism has been described for the ErbB-4 receptor whose cleavage is necessary for receptor degradation by the proteasome machinery (Vecchi and Carpenter, 1997) .
Finally, it is possible that cleavage represents a physiological mechanism for the modulation of receptor activity. Assuming that the TrkCNC2 receptor is able to transduce a signal by itself, as suggested by previous reports (Hapner et al., 1998; Menn et al., 1998 Menn et al., , 2000 , this processing may generate a membrane-anchored fragment (p20
) constituting the transducing molecule. This has already been documented for the Notch receptor, cleaved in its intracellular region in response to Delta binding. Consequently, the newly formed soluble intracellular fragment is capable of interacting with cytosolic proteins to transduce signals (Schroeter et al., 1998) . On the other hand, the consequence of cleavage Figure 5 The endogenous TrkCNC2 protein is also cleaved. Primary culture of cortical neurons (CN) was performed as previously described (Menn et al., 2000) . Briefly, cerebral cortex of 16-day-old mouse embryos was dissociated by trituration and enzymatic digestion with 20 mg/ml DNAse I and 1.25% trypsin. Cells were then seeded onto poly-dl-ornithine-coated dishes in high-glucose DMEM/Ham's F12 medium (50 : 50, Gibco-BRL), supplemented with 10% horse serum. The medium was replaced by N2-DMEM/F12 medium (high-glucose DMEM/Ham's F12 supplemented with 5 mg/ml insulin, 20 nm progesterone, 100 mm putrescine, 30 nm sodium selenite and 100 mm transferrin) 3 h after plating, and cultured for 5 days. Lysates of cultured cortical neurons and brain (Br) extracts were analysed by immunoprecipitation and Western blot using anti-Trk kinase antibodies (1 : 2000, Santa Cruz) or anti-NC2 antibodies. Stars indicate nonspecific bands might be to produce a nontransducing membranebound fragment containing mostly intracellular sequences that act as a dominant negative by forming heterodimers with the TrkC catalytic isoform.
In conclusion, we propose that TrkCNC2 cleavage represents a novel mechanism of modulating NT-3 biological effects on its target cell.
